{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'monitor, the consulting psychiatrist, and/or sponsor to determine whether the patient', 'should continue in the study.', 'Suicidal behavior', 'Actual attempt:', 'If patients report any suicidal behavior that is an actual attempt as assessed in the C-', 'SSRS, they will be evaluated immediately by the study investigator, referred for', 'psychiatric evaluation, and terminated from the study.', 'Interrupted attempt, aborted attempt, or Preparatory Acts or Behavior:', 'If patients report any suicidal behavior that is interrupted, aborted, or preparatory as', 'assessed in the C-SSRS, they will be evaluated immediately by the study investigator and', 'referred for psychiatric evaluation. In cases where it is determined in the psychiatric', 'evaluation that IMP did not contribute to changes in suicidal behavior, the investigator', 'will consult with the medical monitor, the consulting psychiatrist, and/or sponsor to', 'determine whether the patient should continue in the study.', 'A reference sample is provided in Appendix E.', '7.2.3.', \"Children's Depression Inventory, Second Edition\", 'The CDI-2 (parent and self-report profiles) is administered at screening, baseline, and weeks 2,', '4, 6, 9, 12, and 13. As the CDI-2 is designed for children 7 to 17 years of age, children 6 years of', 'age at baseline will not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.', 'The CDI-2 Self-report is a 28-item self-report questionnaire assessing depressive symptoms in', 'children 7 to 17 years of age with basic reading and comprehension skills. In the CDI-2, children', 'are asked to choose 1 of 3 statements that most closely aligns with their feelings in the previous', '2 weeks. The questionnaire covers both the major and minor symptoms of depression as outlined', 'in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Sun', 'and Wang 2015).', 'The CDI-2 Parent is a 17-item questionnaire administered to parents to assess depression-related', \"behaviors observed in their children. In the CDI-2 Parent, parents are asked to rate their child's\", 'behaviors in the past 2 weeks on a 4-point Likert scale from \"not at all\" to \"much or most of the', 'time\". The questionnaire allows for the division of depressive symptoms into functional', 'problems and emotional problems (Sun and Wang 2015).', 'A reference sample is provided in Appendix D.', '7.3.', 'Pregnancy', 'Any female patient becoming pregnant during the study will discontinue IMP.', 'All pregnancies of female patients participating in the study that occur during the study, or', 'within 14 days after the end of the study, are to be reported immediately to the individual', 'identified in the Clinical Study Personnel Contact Information section of this protocol, and the', 'investigator must provide the sponsor (LSO/Syneos Health) with the completed pregnancy form.', '87']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The process for reporting a pregnancy is the same as that for reporting a serious adverse event', 'but using the pregnancy form (see Section 7.1.5.3).', 'The investigator is not required to report patients who are found to be pregnant between', 'screening and baseline, provided no IMP was given. All female patients who become pregnant', 'will be monitored for the outcome of the pregnancy (including spontaneous, elective, or', 'voluntary abortion). If the pregnancy continues to term, the outcome (health of the infant up to', '8 weeks of age), including details of birth and presence or absence of any birth defect, congenital', 'abnormalities, or maternal and newborn complications, will be reported to the sponsor. Any', 'complication of pregnancy during the study and any complication of pregnancy that the', 'investigator becomes aware of after withdrawal from the study will be reported as an adverse', 'event or serious adverse event, as appropriate.', 'If the pregnancy in the female patients participating in the study does not continue to term, 1 of', 'the following actions will be taken:', 'For a spontaneous abortion, report as a serious adverse event.', 'For an elective abortion due to developmental anomalies, report as a serious adverse', 'event.', 'For an elective abortion not due to developmental anomalies, report on the pregnancy', 'form; do not report as an adverse event.', '7.4.', 'Medication Error and Special Situations Related to the', 'Investigational Medicinal Product', 'Any administration of IMP that is not in accordance with the study protocol should be reported', 'on the CRF either as a violation, if it meets the violation criteria specified in the protocol', '(Section 11.1.2), or as a deviation, in the patients source documents, regardless of whether or not', 'an adverse event occurs as a result. All instances of incorrect medication administration should', 'be categorized on the CRF as \"Non-Compliance with IMP\"', 'The following are types of medication errors and special situations:', '1. Medication error: Any unintentional error in the prescribing, dispensing, or', 'administration of a medicinal product while in the control of the healthcare professional,', 'patient, or consumer.', '2. Overdose: Administration of a quantity of a medicinal product given per administration', 'or cumulatively which is above the maximum recommended dose according to the', 'authorized product information. Clinical judgment should always be applied. Any dose of', 'IMP (whether the test IMP or placebo), whether taken intentionally or unintentionally in', 'excess of the dose prescribed, must be immediately reported to the sponsor.', '3. Misuse: Situations where the IMP is intentionally and inappropriately used not in', 'accordance with the authorized product information.', '4. Abuse: Persistent or sporadic, intentional excessive use of IMP, which is accompanied by', 'harmful physical or psychological effects.', '88']\n\n###\n\n", "completion": "END"}